Siam Bioscience breaks silence on Thai vaccine deal after Thanathorn criticism


BANGKOK (The Nation/ANN): Siam Bioscience on Monday (Jan 25) released a statement following criticism by Progressive Movement leader Thanathorn Juangroongruangkit over its role in Thailand’s Covid-19 vaccine programme.

Last Monday Thanathorn slammed the government for slowness in providing vaccines, and questioned the transparency of giving a company owned by the Crown Property Bureau – Siam Bioscience – the right to manufacture the AstraZeneca vaccine locally.

Thanathorn alleged documents show there was no selection process or comparison made between companies before Siam Bioscience was handed the task.

Last Wednesday, the government filed a charge of lese majeste against Thanathorn over his comments.

On Monday, Siam Bioscience clarified steps that led to the deal, though did not respond directly to Thanathorn’s allegations.

“In October 2020 Siam Bioscience, SCG [Siam Cement Group], AstraZeneca and the Public Health Ministry signed a Letter of Intent to demonstrate their joint commitment to make this vaccine available in Southeast Asia, ” said the company statement.

“This was followed by a contract manufacturing agreement between AstraZeneca and Siam Bioscience. This agreement also signifies that Siam Bioscience met AstraZeneca’s high technical, operational and ethical standards.

"Through technology transfer from AstraZeneca, Siam Bioscience is now part of AstraZeneca’s worldwide network of vaccine manufacturing partners.”

Siam Bioscience also outlined its relevant experience:“AstraZeneca’s Covid-19 vaccine is a modified adenoviral vector grown in mammalian cells. Siam Bioscience has experience with manufacturing and exporting products that use such mammalian cell technology.

Our facilities comply with multiple international standards, provide an integrated solution for every step of the process and, as the largest biopharmaceutical manufacturer in Thailand, we have the potential to expand our capacity in the future.”

The company said it was manufacturing the vaccine under a “no profit, no loss” policy for the duration of the pandemic, in line with AstraZeneca’s own commitment.

“The mission to manufacture Covid-19 vaccine is supported by the National Vaccine Institute, Public Health Ministry with a budget of almost Bt600 million, and an additional Bt100 million budget from Siam Cement Group in order to prepare the facilities for manufacturing AstraZeneca vaccine as soon as possible.” - The Nation/Asia News Network

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

Thailand , Siam Bioscience , Thanathorn , vaccine

   

Next In Aseanplus News

Japan hosts Quad summit seeking unity on countering China
Biden to new Australian PM: you can 'fall asleep' now
US, Quad partners announce pact to curb illegal fishing
Taiwan man invents stroller for fish to 'explore other worlds'
Indonesia has no plan to reduce palm oil in biodiesel mix: Minister
Tight material supply impedes Vietnam textile exports
Singapore to minimise impact from Malaysia's chicken shortage
Thailand records 4,144 Covid-19 cases and 36 deaths
Singapore to up chicken supply from other sources as Malaysia halts export
‘Be alert over monkeypox’

Others Also Read